Advertisement

Management of Cervical Neoplasia

  • William RobinsonIII
Part of the Cancer Treatment and Research book series (CTAR, volume 104)

Abstract

Innovations in surgical and radio-therapy have resulted in improvements in both patient survival and physician understanding of the pathogenesis of cervical neoplasia. Recognition of the existence of a preinvasive component of cervical neoplasia, and the development of cytologic screening have resulted in great changes in the way cervical neoplasia is managed in the United States. Cytologic testing, in the form of the pap smear, has been utilized to diagnose precancerous disease, for which treatment is almost always effective in preventing the subsequent occurrence of invasive cancer. As a result, in the past fifty years the treatment of precancerous cervical neoplasia in the U.S. has become much more common, while the incidence of invasive cervical cancer has fallen dramatically.

Keywords

Human Immunodeficiency Virus Cervical Cancer Human Immunodeficiency Virus Infection Human Papilloma Virus Cervical Intraepithelial Neoplasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    National Institutes of Health. Cervical Cancer, NIH Consensus Statement, 14(1):1–38, Apr 1–2, 1996.Google Scholar
  2. 2.
    Centers for Disease Control: HIV/AIDS Surveillance Report, 10(1):1–37, 1998.Google Scholar
  3. 3.
    Maiman M, Fruchter RG, Serur E, Boyce JG. Prevalence of human immunodeficiency virus in a colposcopy clinic. JAMA 1988;260:2214–2215.PubMedCrossRefGoogle Scholar
  4. 4.
    Cherry ML, Robinson WR. HIV screening in an urban colposcopy clinic. ACOG Dist VII meeting, San Antonio, Oct. 1993.Google Scholar
  5. 5.
    Maiman M, Fruchter RG, Serur E, Remy JC, Feuer G, Boyce J. Human immunodeficiency virus infection and cervical neoplasia. Gynecol Oncol 38:377–382, 1990.PubMedCrossRefGoogle Scholar
  6. 6.
    Centers for Disease Control: 1993 revised classification system for HIV infection and expanded case surveillance definition for AIDS among adolescents and adults. JAMA 269:729–730, 1993.CrossRefGoogle Scholar
  7. 7.
    Centers for Disease Control:MMWR Morb Mortal Wkly Rep 44(5):81–83, 1995.Google Scholar
  8. 8.
    International Federation of Gynecology and Obstetrics: Annual Report, 1986.Google Scholar
  9. 9.
    Cramer DW, Cutler JJ. Incidence and histopathology of malignancies of the female genital organs in the United States. Am J Obstet Gynecol 118:443, 1974.PubMedGoogle Scholar
  10. 10.
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer Statistics, 1999. CA Cancer J Clin 49:8–31, 1999.PubMedCrossRefGoogle Scholar
  11. 11.
    Ferlay J, Parkin DM, Pisani P. GLOBOCAN: Cancer incidence and mortality worldwide. Lyon, France, International agency for Research on Cancer, IARC Cancer Base No. 3, 1998.Google Scholar
  12. 12.
    Nkowane BM. Prevalence and incidence of HIV infection in Africa: A review of data published in 1990. AIDS 5(suppl 1)s7–15, 1991.CrossRefGoogle Scholar
  13. 13.
    La Ruche G, Ramon R, Mensah-Ado I, Bergeron C, Diomonde M, Sylla-Koko F, Ehouman A, Toure-Coulibaly K, Welffens-Ekra C, Dabis F. Squamous intraepithelial lesions of the cervix, invasive cervical carcinoma, and immunosuppression induced by human immunodeficiency virus in Africa. Dyscer-CI Group. Cancer 82(12):2401–2408, 1998.Google Scholar
  14. 14.
    Motti PG, Dallabetta GA, Daniel RW, Canner JK, Chiphangwi JD, Liomba GN, Yang L, Shah KV. Cervical abnormalities, human papillomavirus, and human immunodeficiency virus infections in women in Malawi. J Infect Dis 173(3):714–717, 1996.PubMedCrossRefGoogle Scholar
  15. 15.
    Barron BA, Richart RM. An epidemiologic study of cervical neoplastic disease: based on a self-selected sample of 7000 women in Barbados, West Indies. Cancer 27:978–983, 1971.PubMedCrossRefGoogle Scholar
  16. 16.
    Kolstad P, Klem V. Long-term follow-up of 1121 cases of carcinoma in situ. Obstet Gynecol 48:125–129, 1976.PubMedGoogle Scholar
  17. 17.
    Mclndoe WA, McLean MR, Jones RW, Mullins PR. The invasive potential of carcinoma in situ of the cervix. Obstet Gynecol 64:451–458, 1984.Google Scholar
  18. 18.
    Melnikow J, Nuovo J, Willan AR, Chan BKS, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 92:727–735, 1998.PubMedCrossRefGoogle Scholar
  19. 19.
    Laimons L. The biology of human papillomaviruses: From warts to cancer. Infectious Agents and Disease 2:74–86, 1993.Google Scholar
  20. 20.
    zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Current Topics in Microbiology and Immunology 186:131–156, 1994.PubMedCrossRefGoogle Scholar
  21. 21.
    Vernon S, Hart CE, Reeves WC, Icenogle JP. The HIV-1 Tat protein enhances E2-dependent human papillomavirus 16 transcription. Virus Research 27:133–145, 1993.PubMedCrossRefGoogle Scholar
  22. 22.
    Holcomb K, Maiman M, DiMaio T, Gates J. Rapid progression to invasive cervix cancer in a woman infected with the human immunodeficiency virus. Obstet Gynecol 91:848–850, 1998.PubMedCrossRefGoogle Scholar
  23. 23.
    Belafsky P, Clark R, Kissinger P, Torres J. The natural history of low grade squamous intraepithelial lesions in women infected with human immunodeficiency virus. J Acquire Immune Defic Synd 11:511–512, 1996.CrossRefGoogle Scholar
  24. 24.
    Maiman M, Tarricone N, Viera J, Suarez J, Serur E, Boyce JG. Colposcopic evaluation of human immunodeficiency virus-positive women. Obstet Gynecol 78:84–88, 1991.PubMedGoogle Scholar
  25. 25.
    Shafer A, Friedmann W, Mielke M, Schwartlander B, Koch MA. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am J Obstet Gynecol 164:593–599, 1991.Google Scholar
  26. 26.
    Robinson WR, Barnes SE, Adams S, Perrin MS. Histology/cytology discrepancies in HIV-infected obstetric patients with normal pap smears. Gynecol Oncol 65:430–433, 1997.PubMedCrossRefGoogle Scholar
  27. 27.
    Olaitan A, Mocroft A, McCarthy K, Phillips A, Reid W, Johnson M. Cervical abnormality and sexually transmitted disease screening in human immunodeficiency virus-positive women. Obstet Gynecol 89:71–75, 1997.PubMedCrossRefGoogle Scholar
  28. 28.
    Maiman M, Fruchter RG, Sedlis A, Feldman J, Chen P, Burk RD, Minkoff H. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynecol Oncol 69:233–239, 1998.CrossRefGoogle Scholar
  29. 29.
    Alloub MI, Barr BB, McLauren KM, Smith IW, Bunney MH, Smart GE. Human papillomavirus and cervical intraepithelial neoplasia in women with renal allografts. Br J Med 298:153–156, 1989.CrossRefGoogle Scholar
  30. 30.
    Adachi A, Fleming I, Burk RD, Ho GF, Klein RS. Women with human immunodeficiency virus infection and abnormal Papanicolaou smears: A prospective study of colposcopy and clinical outcome. Obstet Gynecol 81:372–377, 1993.PubMedGoogle Scholar
  31. 31.
    Boardman LA, Peipert JF, Cooper AS, Cu-Uvin S, Flanagan T, Raphael SI. Cytologic-histologic discrepancy in human immunodeficiency virus-positive women referred to a colposcopy clinic. Obstet Gynecol 84:1016–1020, 1994.PubMedGoogle Scholar
  32. 32.
    Wright TC, Ellerbrock TV, Chaisson MA, Van Devanter N, Sun XW, and the New York Cervical Disease Study. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: Prevalence, Risk factors, and validity of Papanicolaou smears. Obstet Gynecol 84:591–597, 1994.PubMedGoogle Scholar
  33. 33.
    Centers for Disease Control: Sexually Transmitted Disease Guidelines. Morb Mort Wkly Rep 42:83–91, 1993.Google Scholar
  34. 34.
    Palefsky JM. Human papilloma virus associated anogenital neoplasia and other solid tumors in human immunodeficiency virus-infected individuals. Curr Opin Oncol 3:881–885, 1991.PubMedCrossRefGoogle Scholar
  35. 35.
    Wright TC, Moscarelli RD, Dole P, Ellerbrock TV, Chaisson MA, Vandevanter N. Significance of mild cytologic atypia in women infected with human immunodeficiency virus. Obstet Gynecol 87:515–519, 1996.PubMedCrossRefGoogle Scholar
  36. 36.
    Schwartz LB, Cargangiu ML, Bradham L, Schwartz PE. Rapidly progressive squamous cell carcinoma of the cervix coexisting with human immunodeficiency virus infection: Clinical opinion Gynecol Oncol 41:255–258, 1991.CrossRefGoogle Scholar
  37. 37.
    Singh GS, Aikens JK, Deger R, King S, Mikuta JJ. Metastatic cervical cancer and pelvic inflammatory disease in an AIDS patient. Gynecol Oncol 54:372–376, 1994.PubMedCrossRefGoogle Scholar
  38. 38.
    Burghardt E, Holzer E. Treatment of carcinoma in situ: Evaluation of 1609 cases. Obstet Gynecol 55:539–545, 1980.PubMedGoogle Scholar
  39. 39.
    Benedet SL, Miller DM, Nickerson KG. Results of conservative management of cervical intraepithelial neoplasia. Obstet Gynecol 79:105–109, 1992.PubMedGoogle Scholar
  40. 40.
    Heard I, Bergeron C, Jeannel D, Henrion R, Kazatchkine MD. Papanicolaou smears in human immunodeficiency virus-seropositive women during follow-up. Obstet Gynecol 86:749–753, 1995.PubMedCrossRefGoogle Scholar
  41. 41.
    Maiman M, Fruchter RG, Serur E, Levine PA, Arrastia CD, Sedlis A. Recurrent cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women. Obstet Gynecol 82:170–174, 1993.PubMedGoogle Scholar
  42. 42.
    Wright TC, Koulos J, Schnoll F, Swanbeck J, Ellerbrock TV, Chaisson MA, Richart RM. Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: Outcome after LOOP electrosurgical excision. Gynecol Oncol 55:253–258, 1994.PubMedCrossRefGoogle Scholar
  43. 43.
    Fruchter RG, Maiman M, Sedlis A, Bartley L, Camilien L, Arrastia CD. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 87:338–344, 1996.PubMedCrossRefGoogle Scholar
  44. 44.
    Robinson WR, Tirpack JS. The predictive value of LEEP specimens with involved margins for residual dysplasia. Int J Gynecol Cancer 6:140–144, 1996.CrossRefGoogle Scholar
  45. 45.
    Robinson WR, Lund ED, Adams J. The predictive value of LEEP specimen margin status for residual/recurrent cervical intraepithelial neoplasia. Int J Gynecol Oncol 8:109–112, 1998.CrossRefGoogle Scholar
  46. 46.
    Mackerras D, Irwig L, Simpson JM, Weisberg E, Cardona M, Webster F, Walton L, Ghersi D. Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities. Brit J Cancer 79:1448–1453, 1999.PubMedCrossRefGoogle Scholar
  47. 47.
    Romney SL, Ho GY, Palan PR, Basu J, Kadish AS, Klein S, Mikhail M, Hagan RJ, Chang CJ, Burk RD. Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol Oncol 65(3):483–492, 1997.PubMedCrossRefGoogle Scholar
  48. 48.
    Frost L, Skajaa K, Hvidman LE, Fay SJ, Larsen PM. No effect of intralesional injection of interferon on moderate cervical intraepithelial neoplasia. Brit J Obstet Gynecol 97:626–630, 1990.CrossRefGoogle Scholar
  49. 49.
    Yliskowski M, Syrjanen K, Syrjanen S, Saarikoski S, Nethersell A. Systemic alpha-interferon treatment of genital human papillomavirus(HPV) type 6, 11, 16, and 18 infections: double-blind, placebo-controlled trial. Gynecol Oncol 43:55–60, 1991.CrossRefGoogle Scholar
  50. 50.
    Surwit EA, Graham V, Droegemueller W, Alberts D, Chvapil M, Dorr RT, Davis JR, Meyskens FL. Evaluation of topically applied trans-retinoic acid in the treatment of cervical intraepithelial lesions. Am J Obstet Gynecol 143:821–823, 1982.PubMedGoogle Scholar
  51. 51.
    Ruidi C, Aihua D, Peivu B, Zhongru G, Huazao L, Shifeng S, Rui H, Shiping X. Chemoprevention of cancer of the uterine cervix: a study on chemoprevention of retinamide II from cervical precancerous lesions. J Cell Biochem(suppl) 28,29:140–143, 1997.CrossRefGoogle Scholar
  52. 52.
    Meyskens FL, Surwit E, Moon TE, Childers JM, Davis JR, Dorr RT, Johnson CS, Alberts DS. Enhancement of regression of cervical intraepithelial neoplasia II(moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst 86:539–543, 1994.PubMedCrossRefGoogle Scholar
  53. 53.
    Kreb HB, Hans B. Prophylactic topical 5-fluorouracil following treatment of human papillomavirus associated lesions of the vulva and vagina. Obstet Gynecol 68:837–841, 1986.Google Scholar
  54. 54.
    Sillman FH, Sedlis A. Anogenital papillomavirus infection and neoplasia in immunodeficient women: An update. Obstet Gynecol Clin North am 14:537–558, 1987.PubMedGoogle Scholar
  55. 55.
    Maiman M, Watts H, Andersen J. Vaginal 5-Flourouracil for high-grade cervical dysplasia in HIV-infected women: A randomized trial. Obstet Gynecol, in press.Google Scholar
  56. 56.
    Micheals SH, Clark R, Kissinger P. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med 339:405–406, 1998.CrossRefGoogle Scholar
  57. 57.
    Centers for Disease Control: MMWR Morb Mortal Wldy Rep 46:861–866, 1997.Google Scholar
  58. 58.
    Korvick JA, Stratton P, Spino K, Wofsy C. Women’s participation in AIDS Clinical Trials Group(ACTG) trials in the USA-enough or still too few? Int Conf AIDS 9(1):561(abstract no. PO-B44–2555) 1993.Google Scholar
  59. 59.
    Bongain A, Magnaldo S, Galiba E, Cottalorda J, Dellamonica P, Gillet JY. Immunological parameters and cervical intraepithelial neoplasia(CIN) in HIV1+ women. Int Conf AIDS. 12:547(abstract no. 32134), 1998.Google Scholar
  60. 60.
    Delmas MC, Agarossi A, Bergeron C, Meier F, Paavonen J, Poveda JD, Van Den Hoek JA. Incidence of squamous intraepithelial lesions(SIL) in HIV infected women. Int Conf AIDS. 12:324(abstract no. 623/22306) 1998.Google Scholar
  61. 61.
    Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 12:1459–1464, 1998.PubMedCrossRefGoogle Scholar
  62. Robinson WR, Hamilton CA, Micheals SH, Kissinger P. The effect of highly active antiretroviral therapy on cervical intraepithelial neoplasia in human immunodeficiency virus-infected women. Am J Obstet Gynecol, in press.Google Scholar
  63. 63.
    Klevens RM, Fleming PL, Mays MA, Frey R. Characteristics of women with AIDS and invasive cervical cancer. Obstet Gynecol 88:269–273, 1996.PubMedCrossRefGoogle Scholar
  64. 64.
    Maiman M, Fruchter RG, Clark M, Arrastia CD, Matthews R. Cervical cancer as an AIDS defining illness. Obstet Gynecol 89:76–80, 1997.PubMedCrossRefGoogle Scholar
  65. 65.
    DeVito JR, Robinson WR. Gynecological surgical outcomes among asymptomatic human immunodeficiency virus-infected women and uninfected control subjects. J La State Med Soc 147:108–112, 1995.Google Scholar
  66. 66.
    Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ. Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 3:1079–1085, 1985. Oncol 15:165–171, 1997.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • William RobinsonIII
    • 1
  1. 1.The Don and Sybil Harrington Cancer CenterAmerica

Personalised recommendations